miR Scientific: spotting aggression with RNA in urine

How miR is developing diagnostic, prognostic cancer tests using sncRNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments.

The company's technology, which was spun out of the State University of New York University at Albany, is based on work by co-founder and CSO Martin Tenniswood that ties expression level of specific small non-coding RNA (sncRNA) sequences to cancer biology. Tenniswood

Read the full 742 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE